PARIS (dpa-AFX) - French drug major Sanofi (SNYNF, SNY) announced Monday an
investment of more than 1 billion euros to create new bioproduction capacity at
its various sites in France.

The new investment for biomanufacturing in Val de Marne, Seine-Maritime and
Rhone sites will create more than 500 jobs. It is expected to significantly
strengthen France's ability to control the production of essential medicines
from start to finish, for the present day and into the future.

In Vitry-sur-Seine, Sanofi will invest 1 billion euros to build a new facility
that will double the site's monoclonal antibody production capacity. The company
will produce several biologics in development amongst its 12 potential
blockbusters, in chronic obstructive pulmonary disorder, asthma, multiple
sclerosis or type 1 diabetes, in the site. Sanofi anticipates the creation of
350 jobs as a result of this investment.

At the Le Trait site in Normandy, Sanofi will invest 100 million euros to
develop new capacity for biologics formulation, filling, device assembly and
packaging. The investment will support 150 jobs.

Further, in Lyon Gerland, Sanofi is investing 10 million euros to locate the
production of TZield in France. Tzield is a biologic for type 1 diabetes that
Sanofi acquired in April 2023 and which has been manufactured outside Europe.

The latest investment adds to the company's already committed 2.5 billion euros
in major projects in France to support health sovereignty. With this, the
company has committed more than 3.5 billion euros in total since the Covid-19
pandemic in major projects to keep production of medicines and vaccines in
France for patients around the world.

Paul Hudson, Chief Executive Officer, Sanofi, said, 'With these unprecedented
industrial investments, we remain true to our history by once again choosing
France to produce these future medicines and make them available to patients
around the world. France is, and always will be, at the heart of Sanofi's
strategy.'

Sanofi noted that it carries out more than 60% of its global production in the
European Union and sources only 5% of its active ingredients in Asia.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX